Bio-Rad Laboratories, Inc. (BIO)
NYSE: BIO · IEX Real-Time Price · USD
280.65
-10.21 (-3.51%)
Apr 18, 2024, 1:43 PM EDT - Market open

Bio-Rad Laboratories Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014 2013 - 1994
Net Income
-637.32-3,627.544,2543,8141,759365.61122.2526109.2488.85
Upgrade
Share-Based Compensation
0000000-1.51-3.61-1.35
Upgrade
Other Operating Activities
1,0123,822-3,584.79-3,229.26-1,300.78-80.12-18.11191.5780.58185.82
Upgrade
Operating Cash Flow
374.94194.45669.46584.97457.9285.49104.14216.07186.21273.31
Upgrade
Operating Cash Flow Growth
92.83%-70.95%14.44%27.75%60.39%174.15%-51.80%16.03%-31.87%61.59%
Upgrade
Capital Expenditures
-156.47-112.62-133.69-108.49-98.4-125.51-111.25-141.04-111.92-120.77
Upgrade
Acquisitions
2.5-99.39-125.52-84.42-79.397.23-76.65000
Upgrade
Change in Investments
174.18-994.21-538.17119.6-39.92-68.716.11-72.71-53.58-54.26
Upgrade
Other Investing Activities
--1.38-3.418.82-0-3.8-0.14-1.37-15.48
Upgrade
Investing Cash Flow
20.21-1,207.59-797.38-69.89-208.89-186.98-175.57-213.88-166.87-190.51
Upgrade
Share Issuance / Repurchase
-410.24-198.12-29.37-79.81-11.06-34.7811.6811.288.2415.05
Upgrade
Debt Issued / Paid
-0.471,186-3.02-426.94-1.13-2.96-0.35-0.27-0.28-1.81
Upgrade
Other Financing Activities
-14.94-14.02-23.04-16.3-10.57-10.94-10.99-1.990.63-1.55
Upgrade
Financing Cash Flow
-425.65973.58-55.43-523.04-22.76-48.680.349.028.5811.69
Upgrade
Exchange Rate Effect
0.322.98-12.6412.432.24-0.66-1.09-12.8616.38-12.79
Upgrade
Net Cash Flow
-30.18-36.59-195.984.46228.4949.18-72.19-1.6544.381.7
Upgrade
Free Cash Flow
218.4781.83535.77476.48359.49159.98-7.1175.0374.29152.54
Upgrade
Free Cash Flow Growth
167.00%-84.73%12.44%32.54%124.71%--0.99%-51.30%139.49%
Upgrade
Free Cash Flow Margin
8.18%2.92%18.33%18.72%15.55%6.99%-0.33%3.63%3.68%7.01%
Upgrade
Free Cash Flow Per Share
7.482.7517.9616.0112.055.36-0.242.552.545.28
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).